The oseltamivir phosphate suspension declared by Shandong Xinhua Pharmaceutical Co., Ltd. (00719) obtained a drug registration certificate

Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that recently, the company received the “Drug Registration Certificate” for oseltamivir phosphate suspension approved and issued by the State Drug Administration.

This product is used to treat influenza A and B in patients aged 2 weeks and above (oseltamivir phosphate can effectively treat influenza A and B, but there is not much clinical application data for influenza B). Patients should use it within 48 hours of initial symptoms. This product can also be used to prevent influenza A and B in people aged 1 year and over.

The dry oseltamivir phosphate suspension declared by Xinhua Pharmaceutical obtained a drug registration certificate in December 2025, enriching the company's antiviral drug product line and helping to enhance the company's overall competitiveness.